Received Apr 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
shot site was very itchy; shot site was very red; fever; felt a little sluggish; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site itching in a 75-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis. In APR-2025, the patient received the 1st dose of Shingles vaccine. In APR-2025, less than 2 weeks after receiving Shingles vaccine, the patient experienced injection site itching (Verbatim: shot site was very itchy) and injection site erythema (Verbatim: shot site was very red). On an unknown date, the patient experienced fever (Verbatim: fever) and sluggishness (Verbatim: felt a little sluggish). The outcome of the injection site itching and injection site erythema were resolved (duration 1 week) and the outcome of the fever and sluggishness were resolved (duration 2 days). It was unknown if the reporter considered the injection site itching, injection site erythema, fever and sluggishness to be related to Shingles vaccine. It was unknown if the company considered the injection site itching, injection site erythema, fever and sluggishness to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 21-APR-2025 The case was received from the patient via interactive digital media. The patient was 75 years old and about a week and a half ago had his/her first shingles shot of the two. The patient had a reaction for about a week. The shot site was very red and itchy, about the size of a lid on a jar of mayonnaise. The patient had a little fever felt a little sluggish for a day or two. The patient could not say that he/she was looking forward to the next one.